MGTX vs GLUE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
MGTX · MeiraGTx Holdings$9.00 ▲ 5.76%
GLUE · Monte Rosa Therapeutics$10.57 ▲ 3.12%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- MGTX +5.3%
- GLUE -24.8%
Head to head
| Metric | MGTX | GLUE |
|---|---|---|
| Price | $9.00 | $10.57 |
| Change today | ▲ 5.76% | ▲ 3.12% |
| Market cap | $864.39M | $903.21M |
| Return, 3 months | -30.9% | -33.2% |
| Return, year to date | +13.2% | -32.6% |
| Return, 1 year | +6.3% | -14.1% |
| P/E (TTM) | 10.3 | -7.6 |
| P/B | 4.0 | 1.8 |
| P/E percentile vs own 5y | 96th | 12th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +8,608.6% | -61.3% |
| Net profit growth (YoY) | +514.1% | -253.0% |
| Gross margin | 97.9% | – |
| Operating margin | 46.3% | -633.0% |
| Net margin | 19.9% | -560.9% |
| Return on equity | 72.3% | -42.7% |
| Analyst target vs. price | +148.9% | +157.0% |
| Analyst buy share | 80% | 100% |
| RSI (14) | 38 | 45 |
| 30-day volatility | 58.2% | 58.0% |
| Max drawdown, 1 year | -43.2% | -61.5% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- GLUE is the largest of the group by market value.
- MGTX has returned the most over the past year.
- GLUE carries the lowest trailing P/E.
- MGTX is growing revenue fastest.
- MGTX keeps the most profit per dollar of sales.
- GLUE has been the calmest stock over the last 30 days.